New clin­i­cal trial results for selinexor, a poten­tial new myeloma treat­ment, were released last week by Karyopharm Therapeutics, the U.S. com­pany devel­op­ing the drug.

The new results are “top line” findings, so they are very limited in scope. They are con­sis­tent, how­ever, with the favorable results pre­vi­ously seen in trials of selinexor com­bined with dexa­meth­a­sone in heavily pre­treated multiple myeloma patients. Taken together, the results suggest the selinexor-based two-drug com­bi­na­tion has noteworthy anti-myeloma activity.

Karyopharm (NASDAQ:KPTI) accompanied last week’s release of the new selinexor data with an update on its regu­la­tory plans …

Results from a retrospective Canadian study indicate that combination therapy with Revlimid, Velcade, and dexamethasone is effective for certain heavily pretreated multiple myeloma patients. The findings show that nearly 50 percent of patients with advanced myeloma respond to the three-drug therapy.

The study investigators point out that although most patients with advanced myeloma progress quickly after therapy with Revlimid (lenalidomide), Velcade (bortezomib), and dexamethasone (Decadron), particularly those with high-risk myeloma, some patients experience a “considerable benefit.”

They also note that side effects in this heavily pretreated patient population are …